Melevodopa/carbidopa
Combination dopaminergic medication
From Wikipedia, the free encyclopedia
Melevodopa/carbidopa, sold under the brand name Sirio, is a combination of melevodopa, a prodrug of the dopamine precursor and hence non-selective dopamine receptor agonist levodopa (L-DOPA), and carbidopa, a peripherally selective aromatic L-amino acid decarboxylase (AAAD) inhibitor, which is used in the treatment of Parkinson's disease in Italy.[2][3][4][5][1] It is taken orally in the form of tablets.[1][4]
Trade namesSirio
Other namesCarbidopa/melevodopa; Levodopa methyl ester/carbidopa; CHF-1512; CHF1512; CNP-1512; CNP1512; GT-1512; GT1512; V-1512; V1512
Melevodopa | |
 Carbidopa | |
| Combination of | |
|---|---|
| Melevodopa | Dopamine receptor agonist |
| Carbidopa | Aromatic L-amino acid decarboxylase inhibitor |
| Clinical data | |
| Trade names | Sirio |
| Other names | Carbidopa/melevodopa; Levodopa methyl ester/carbidopa; CHF-1512; CHF1512; CNP-1512; CNP1512; GT-1512; GT1512; V-1512; V1512 |
| Routes of administration | Oral[1] |
